Biohaven - BHVN Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $48.75
Forecasted Upside: 247.47%
Number of Analysts: 9
Breakdown:
0 Sell Ratings
3 Hold Ratings
6 Buy Ratings
0 Strong Buy Ratings

^$14.03 As of 03/24/2023 12:57 PM ET

▲ +0.63 (4.70%)

1 month | 3 months | 12 months

Get New Biohaven Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for BHVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BHVN

^$48.75

▲ +247.47% Upside Potential

This price target is based on 9 analysts offering 12 month price targets for Biohaven in the last 3 months. The average price target is $48.75, with a high forecast of $148.50 and a low forecast of $21.00. The average price target represents a 247.47% upside from the last price of $14.03.

Current Consensus is Buy

The current consensus among 9 polled investment analysts is to buy stock in Biohaven. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
6 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

9/30/2021

0 strong buy ratings
7 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

12/29/2021

0 strong buy ratings
6 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/29/2022

0 strong buy ratings
6 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

6/27/2022

0 strong buy ratings
5 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

9/25/2022

0 strong buy ratings
5 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

12/24/2022

0 strong buy ratings
7 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

2/22/2023

0 strong buy ratings
6 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/24/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
1/24/2023	SVB Leerink	Reiterated Rating	Outperform	$24.00	Low
1/24/2023	SVB Securities	Initiated Coverage	Outperform	$24.00	Low
1/4/2023	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$23.00	Low
12/2/2022	BTIG Research	Initiated Coverage	Buy	$24.00	Low
11/7/2022	Cowen	Set Target		$25.00	Low
11/7/2022	Cowen	Lower Target		$25.00	Low
10/26/2022	Cantor Fitzgerald	Upgrade	Neutral ➝ Overweight	$158.00 ➝ $27.00	Low
10/26/2022	Piper Sandler	Lower Target	Overweight	$23.00 ➝ $21.00	Low
10/12/2022	Piper Sandler	Initiated Coverage	Overweight	$23.00	Low
8/18/2022	Piper Sandler	Downgrade	Overweight ➝ Neutral	$149.00	Low
8/8/2022	Wedbush	Downgrade	Outperform ➝ Neutral	$148.50	Low
5/24/2022	Piper Sandler	Lower Target	NA	$156.00 ➝ $149.00	Low
5/11/2022	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral		Low
5/11/2022	HC Wainwright	Downgrade	Buy ➝ Neutral		Low
5/11/2022	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$150.00	Low
4/6/2022	Morgan Stanley	Lower Target	Equal Weight	$148.00 ➝ $146.00	High
3/3/2022	Mizuho	Boost Target	Buy	$144.00 ➝ $154.00	Low
1/7/2022	HC Wainwright	Reiterated Rating	Buy	$160.00	High
1/7/2022	Morgan Stanley	Boost Target	Equal Weight	$145.00 ➝ $148.00	Medium
1/4/2022	UBS Group	Boost Target		$150.00 ➝ $160.00	High
12/7/2021	HC Wainwright	Reiterated Rating	Buy	$160.00	Low
11/18/2021	Mizuho	Boost Target	Positive ➝ Buy	$135.00 ➝ $144.00	Medium
11/10/2021	Cantor Fitzgerald	Boost Target	Overweight	$165.00 ➝ $177.00	Medium
11/10/2021	Mizuho	Lower Target	Buy	$137.00 ➝ $135.00	Medium
10/19/2021	Morgan Stanley	Boost Target	Equal Weight	$107.00 ➝ $145.00	Low
10/7/2021	SVB Leerink	Reiterated Rating	Buy		Low
10/6/2021	HC Wainwright	Reiterated Rating	Buy	$135.00 ➝ $160.00	Low
10/6/2021	The Goldman Sachs Group	Boost Target	Buy	$151.00 ➝ $170.00	Low
10/5/2021	Mizuho	Reiterated Rating	Buy	$137.00	Low
10/5/2021	Piper Sandler	Boost Target	Overweight	$140.00 ➝ $156.00	Medium
9/13/2021	Cantor Fitzgerald	Boost Target	Overweight	$151.00 ➝ $165.00	High
8/10/2021	UBS Group	Downgrade	Buy ➝ Neutral	$108.00 ➝ $109.00	High
7/16/2021	Morgan Stanley	Boost Target	Equal Weight	$69.00 ➝ $107.00	High
7/12/2021	Mizuho	Boost Target	Buy	$92.00 ➝ $134.00	Low
7/8/2021	HC Wainwright	Boost Target	Buy	$111.00 ➝ $135.00	High
7/7/2021	Cowen	Boost Target	Outperform	$90.00 ➝ $130.00	High
6/1/2021	Cantor Fitzgerald	Boost Target	Overweight	$125.00 ➝ $140.00	High
5/28/2021	Mizuho	Boost Target	Buy	$90.00 ➝ $92.00	Low
5/18/2021	Morgan Stanley	Lower Target	Equal Weight	$76.00 ➝ $69.00	High
5/12/2021	SVB Leerink	Lower Target	Outperform	$115.00 ➝ $105.00	Medium
5/11/2021	Mizuho	Lower Target	Buy	$98.00 ➝ $90.00	Medium
5/3/2021	Mizuho	Lower Target	Buy	$103.00 ➝ $98.00	N/A
4/26/2021	Mizuho	Lower Target	Buy	$103.00 ➝ $98.00	Low
4/19/2021	Morgan Stanley	Boost Target	Equal Weight	$73.00 ➝ $76.00	Medium
3/11/2021	UBS Group	Initiated Coverage	Buy	$108.00	High
3/2/2021	Mizuho	Boost Target	Buy	$93.00 ➝ $103.00	High
3/1/2021	Piper Sandler	Boost Target	Overweight	$90.00 ➝ $110.00	Low
2/5/2021	William Blair	Reiterated Rating	Buy		Medium
1/19/2021	Mizuho	Lower Target		$100.00 ➝ $93.00	High
1/19/2021	HC Wainwright	Lower Target	Buy	$121.00 ➝ $111.00	High
12/29/2020	Cantor Fitzgerald	Boost Target	Overweight	$109.00 ➝ $115.00	N/A
12/16/2020	Morgan Stanley	Boost Target	Equal Weight	$63.00 ➝ $73.00	Medium
12/15/2020	HC Wainwright	Initiated Coverage	Buy	$121.00	Medium
12/7/2020	SVB Leerink	Boost Target	Outperform	$85.00 ➝ $120.00	Medium
11/13/2020	Mizuho	Boost Target	Buy	$82.00 ➝ $100.00	Low
10/13/2020	Wedbush	Boost Target	Outperform	$96.00 ➝ $99.00	Low
10/13/2020	Morgan Stanley	Boost Target	Equal Weight	$57.00 ➝ $63.00	Low
8/24/2020	Morgan Stanley	Lower Target	Equal Weight	$60.00 ➝ $57.00	High
8/10/2020	William Blair	Reiterated Rating	Buy		High
7/15/2020	Morgan Stanley	Boost Target	Equal Weight	$50.00 ➝ $60.00	Low
6/26/2020	Mizuho	Initiated Coverage	Buy	$85.00	Low
6/23/2020	Cantor Fitzgerald	Boost Target	Overweight	$82.00 ➝ $109.00	Low
6/18/2020	Wedbush	Boost Target	Outperform	$74.00 ➝ $94.00	Low
6/15/2020	Cowen	Boost Target	Outperform	$60.00 ➝ $80.00	High
6/9/2020	Mizuho	Reiterated Rating	Buy	$53.00 ➝ $85.00	High
5/20/2020	Mizuho	Reiterated Rating	Buy	$53.00	High
5/11/2020	Cantor Fitzgerald	Boost Target	Overweight	$75.00 ➝ $82.00	Low
5/11/2020	Morgan Stanley	Boost Target	Equal Weight	$46.00 ➝ $50.00	High
5/8/2020	Oppenheimer	Reiterated Rating	Hold	$41.00	Low
4/17/2020	Cowen	Initiated Coverage	Outperform	$45.00	High
4/15/2020	Morgan Stanley	Lower Target	Equal Weight	$49.00 ➝ $46.00	Medium
3/31/2020	Oppenheimer	Lower Target	Market Perform	$48.00 ➝ $37.00	Low
3/13/2020	Wedbush	Boost Target	Outperform	$73.00 ➝ $78.00	High
2/23/2020	Mizuho	Reiterated Rating	Buy	$58.00	High
2/10/2020	The Goldman Sachs Group	Lower Target	Buy	$89.00 ➝ $76.00	Medium
2/10/2020	Oppenheimer	Downgrade	Outperform ➝ Market Perform	$67.00 ➝ $51.00	High
2/5/2020	Mizuho	Initiated Coverage	Buy	$62.00	Low
1/29/2020	Wedbush	Reiterated Rating	Buy	$75.00	High
12/23/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$100.00	Medium
12/17/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$100.00	Medium
12/12/2019	Wedbush	Initiated Coverage	Outperform	$75.00	Low
12/10/2019	William Blair	Reiterated Rating	Buy		Low
12/6/2019	SVB Leerink	Boost Target	Positive ➝ Outperform	$62.00 ➝ $64.00	Medium
11/27/2019	Wedbush	Initiated Coverage	Outperform	$75.00	N/A
11/21/2019	Wedbush	Initiated Coverage	Outperform	$75.00	High
10/28/2019	Cantor Fitzgerald	Boost Target	Overweight	$87.00 ➝ $92.00	High
10/9/2019	Oppenheimer	Set Target	Buy	$67.00	N/A
9/17/2019	William Blair	Reiterated Rating	Buy		Low
9/4/2019	Cantor Fitzgerald	Set Target	Buy	$87.00	Low
9/4/2019	The Goldman Sachs Group	Set Target	Buy	$89.00	Low
8/9/2019	Morgan Stanley	Set Target	Hold	$50.00	High
7/22/2019	Morgan Stanley	Lower Target	Equal Weight	$55.00 ➝ $51.00	High
7/15/2019	Morgan Stanley	Set Target	Hold	$55.00	Low
6/19/2019	Oppenheimer	Set Target	Buy	$68.00	Medium
5/31/2019	Barclays	Reiterated Rating	Hold	$55.00	Low
5/14/2019	Morgan Stanley	Boost Target	Equal Weight	$55.00 ➝ $57.00	High
5/8/2019	Needham & Company LLC	Boost Target	Buy	$70.00	High
5/8/2019	Piper Jaffray Companies	Boost Target	Overweight	$75.00 ➝ $100.00	High
5/6/2019	The Goldman Sachs Group	Initiated Coverage	Buy	$92.00 ➝ $92.00	High
4/23/2019	SVB Leerink	Boost Target	Outperform	$50.00 ➝ $67.00	Medium
4/15/2019	Oppenheimer	Boost Target	Outperform ➝ Outperform	$54.00 ➝ $70.00	Low
4/9/2019	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$49.13	Low
3/19/2019	Barclays	Reiterated Rating	Hold	$52.00	Medium
3/19/2019	Oppenheimer	Reiterated Rating	Buy		Low
3/18/2019	Piper Jaffray Companies	Set Target	Buy	$75.00	Low
3/6/2019	Cantor Fitzgerald	Boost Target	Overweight	$82.00	High
3/4/2019	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$48.00 ➝ $56.00	Medium
2/8/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$75.00	High
12/28/2018	Oppenheimer	Lower Target	Outperform	$63.00 ➝ $54.00	Low
12/10/2018	Cantor Fitzgerald	Set Target	Buy	$65.00	Low
12/10/2018	Piper Jaffray Companies	Set Target	Buy	$65.00	Medium
12/10/2018	Oppenheimer	Set Target	Buy	$63.00	Low
12/3/2018	Oppenheimer	Set Target	Buy	$63.00	High
12/3/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$65.00	High
11/29/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$65.00	High
11/27/2018	Cantor Fitzgerald	Set Target	Overweight ➝ Buy	$55.00	High
11/15/2018	Cantor Fitzgerald	Lower Target	Overweight ➝ Buy	$57.00 ➝ $55.00	High
11/15/2018	William Blair	Reiterated Rating	Outperform		High
11/14/2018	Piper Jaffray Companies	Set Target	Buy	$65.00	High
11/12/2018	SVB Leerink	Initiated Coverage	Outperform	$50.00	Low
11/12/2018	Oppenheimer	Initiated Coverage	Buy	$63.00	Low
10/24/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$65.00	High
10/18/2018	Cantor Fitzgerald	Set Target	Buy	$57.00	Low
10/12/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$57.00	High
10/11/2018	Morgan Stanley	Reiterated Rating	Buy	$47.00	High
10/1/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$57.00	Low
9/12/2018	Cantor Fitzgerald	Set Target	Buy	$57.00	High
9/12/2018	Piper Jaffray Companies	Set Target	Buy	$65.00	High
9/11/2018	Morgan Stanley	Boost Target	Overweight ➝ Overweight	$44.00 ➝ $45.00	High
8/23/2018	Cantor Fitzgerald	Initiated Coverage	Overweight	$55.00	Medium
8/17/2018	Needham & Company LLC	Reiterated Rating	Buy	$48.00	Low
8/16/2018	Piper Jaffray Companies	Set Target	Buy	$48.00	High
7/13/2018	Morgan Stanley	Boost Target	Overweight	$39.00 ➝ $44.00	High
7/12/2018	Cantor Fitzgerald	Boost Target	Overweight ➝ Overweight	$42.00 ➝ $50.00	Medium
7/2/2018	Needham & Company LLC	Boost Target	Buy	$36.00 ➝ $48.00	Medium
6/28/2018	Cantor Fitzgerald	Set Target	Buy	$42.00	Low
6/19/2018	Barclays	Boost Target	Equal Weight	$40.00	Low
6/14/2018	Cantor Fitzgerald	Reiterated Rating	Overweight		Low
6/11/2018	Cantor Fitzgerald	Initiated Coverage	Buy	$42.00	High
6/8/2018	Piper Jaffray Companies	Set Target	Buy	$48.00	High
5/16/2018	Needham & Company LLC	Reiterated Rating	Buy	$36.00	Low
4/5/2018	Barclays	Downgrade	Overweight ➝ Equal Weight	$30.00 ➝ $25.00	Medium
3/26/2018	Piper Jaffray Companies	Reiterated Rating	Buy		High

(Data available from 3/24/2018 forward)

News Sentiment Rating

0.97 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

5 very positive mentions
8 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

8/26/2022

1 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/25/2022

5 very positive mentions
10 positive mentions
6 negative mentions
4 very negative mentions

Mentions as of

10/25/2022

3 very positive mentions
6 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

11/24/2022

2 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/24/2022

2 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/23/2023

7 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/22/2023

5 very positive mentions
2 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

3/24/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an irreversible myeloperoxidase enzyme inhibitor for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial to treat spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in Sept 2022. The company was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.

Today's Range

Now: $14.03

$13.17

$14.13

50 Day Range

MA: $16.34

$12.94

$19.20

52 Week Range

Now: $14.03

$5.54

$20.57

Volume

302,811 shs

Average Volume

992,706 shs

Market Capitalization

$956.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Biohaven?: The following Wall Street sell-side analysts have issued stock ratings on Biohaven in the last twelve months: BTIG Research, Cantor Fitzgerald, Cowen Inc, Cowen Inc., HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, SVB Leerink LLC, SVB Securities, and Wedbush.
View the latest analyst ratings for BHVN.
What is the current price target for Biohaven?: 10 Wall Street analysts have set twelve-month price targets for Biohaven in the last year. Their average twelve-month price target is $48.75, suggesting a possible upside of 263.8%. Wedbush has the highest price target set, predicting BHVN will reach $148.50 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $21.00 for Biohaven in the next year.
View the latest price targets for BHVN.
What is the current consensus analyst rating for Biohaven?: Biohaven currently has 3 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BHVN will outperform the market and that investors should add to their positions of Biohaven.
View the latest ratings for BHVN.
What other companies compete with Biohaven?: Other companies that are similar to Biohaven include uniQure, Geron, Merus, EQRx and Albireo Pharma. Learn More about companies similar to Biohaven.
How do I contact Biohaven's investor relations team?: Biohaven's physical mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company's listed phone number is 203-404-0410 and its investor relations email address is [email protected] The official website for Biohaven is www.biohavenpharma.com. Learn More about contacing Biohaven investor relations.

Biohaven - BHVN Stock Price Target and Predictions

Analyst Price Target for BHVN

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.97 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Biohaven?

What is the current price target for Biohaven?

What is the current consensus analyst rating for Biohaven?

What other companies compete with Biohaven?

How do I contact Biohaven's investor relations team?